A Phase 3 interventional study of Placebo and Onradivir tablet in Influenza, sponsored by Ruijin Hospital. Recruiting at 1 site in China. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Ruijin Hospital · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in Influenza, Human with a site in China — 30 open to participants now, 37 under way, 10 of them phase 3. Influenza, Human · China.
Among the 173 studies in Influenza, Human with a site in China, this one is the 114th largest by planned enrollment of the 157 interventional ones that give a count, is one of 13 that started in 2025, is one of 46 in phase 3, reaches primary completion later than 20 of the 36 other live ones, and was the 147th registered.
2,361 studies on the registry are indexed under Influenza, Human; 186 are open to participants now.
Browse Influenza, Human studies →30 of the 173 studies in Influenza, Human with a site in China are open now. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in China
Ages 18–45 · Women only · Healthy volunteers
Hoffmann-La Roche · Sites in China
Ages 5+ · Healthy volunteers
Ab&B Bio-tech Co., Ltd.JS · Sites in China
Ages 6 mo+ · Healthy volunteers
Shanghai Institute Of Biological Products · Sites in China
Ages 60+ · Healthy volunteers
Capital Medical University · Sites in China
Ages 12+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 124 Influenza, Human studies recruiting now, 67 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 69 take healthy volunteers.
This study: 12 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 22 · Phase 3 49 · Phase 4 43
First in 2004; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 360 across the 157 interventional studies, 230 across the 14 observational. Of the 115 that completed or were terminated, 9 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 173 have an industry lead sponsor. The 10 most frequent:
Ruijin Hospital is the lead sponsor of 682 studies on the registry; 389 are open to participants now.
Ruijin Hospital has 1 study filed under Influenza, Human — fewer than ten, so there is no comparison to draw.
14 of the studies in Influenza, Human with a site in China that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07229547Phase 3Ruijin HospitalA Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Safety and Efficacy of Onradivir Tablets in Participants Aged 12 to 17 Years With Uncomplicated Influenza A. | 2026-12-01 |
| NCT07236814Phase 3Capital Medical UniversitySuraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting | 2027-03-01 |
| NCT07893847Phase 3Capital Medical UniversityEvaluation of the Efficacy and Safety of 102D-6 in the Treatment of Acute Uncomplicated Influenza | 2027-03-30 |
| NCT07827599Phase 3Hoffmann-La RocheA Study to Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants | 2027-04-30 |
| NCT06574503Phase 3Jiangxi Qingfeng Pharmaceutical Co. Ltd.Study to Assess the Efficacy and Safety of GP681 Versus Placebo for Postexposure Prophylaxis Against Influenza | 2027-07-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 173 studies in Influenza, Human with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and safety of Onradivir Tablets in participants aged 12 to 17 years with influenza A virus infection.
The trial plans to enroll approximately 150 adolescent participants (12-17 years) with uncomplicated influenza A, confirmed by rapid antigen/nucleic acid testing and within 48 hours of symptom onset. Eligible participants who meet the inclusion criteria and do not meet any exclusion criteria will be randomized in a 2:1 ratio to receive either Onradivir Tablets or placebo once daily for 5 consecutive days.
The study consists of a screening period, a treatment period, and a safety follow-up period. Each participant will be followed up until Day 14 after the first dose. Nasopharyngeal swabs will be collected at screening, Day 2, Day 4, Day 5, and Day 10 for virological testing, including:
Viral load measurement by reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Viral titer determination by culture assay (50% tissue culture infectious dose, TCID₅₀)
Throughout the treatment and safety follow-up periods, participants will record body temperature, influenza symptom scores, and daily activity scores using a diary card. Clinical laboratory tests will be performed at screening, Day 5, and Day 15. Physical examinations and vital signs measurements will be conducted at each follow-up visit. Adverse events and concomitant medications will be documented throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-
All participants must meet all of the following criteria:
Aged 12 to 17 years (inclusive), regardless of gender.
Diagnosed with influenza A based on the following criteria:
Onset of the first influenza symptom/sign occurring within ≤48 hours before randomization. Influenza symptoms/signs include fever (based on participant-reported data, body temperature ≥37.5°C), headache, muscle or joint pain, fatigue, cough, sore throat, and nasal congestion.
Participant's parent/legal guardian and the participant themselves provide signed before the trial, with full understanding of the trial content, procedures, and potential adverse reactions.
In the investigator's judgment, the participant and their parent/legal guardian are willing and able to comply with the study protocol requirements.
Exclusion Criteria:
Judged by the investigator as having severe or critical influenza.
Having allergic constitution, known allergy to Anladiwei or paracetamol, and/or clinically suspected intolerance, or having .
Difficulty swallowing the product, or history of gastrointestinal diseases that severely affect drug absorption (including but not limited to reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, partial gastrectomy, etc.).
History of febrile seizures.
High-risk population for severe cases, defined as having any of the following conditions:
Concurrent conditions requiring treatment with medications containing aspirin or salicylates.
History of allergic diseases requiring regular use of antihistamines or other prohibited medications; or occurrence of acute respiratory infection, bronchitis, otitis media, or sinusitis within 2 weeks before onset (appearance of the first influenza symptom/sign); or presence of respiratory symptoms (cough, nasal congestion, runny nose, sore throat) within 1 week before onset.
Presence of suspected pharyngoconjunctival fever, herpangina, measles, purulent tonsillitis, or other respiratory infectious diseases or communicable diseases.
Suspected co-infection requiring systemic treatment, in addition to influenza A virus infection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo Group: Take the Onradivir Tablets matching placebo once daily, 3 tablets per dose, for a total of 5 days (5 doses).
Drug: Placebo
Onradivir Tablets Group: Take Onradivir Tablets once daily, 600 mg (3 tablets) per dose, for a total of 5 days (5 doses).
Drug: Onradivir tablet
A placebo that resembles Onradivir tablet in appearance, weight, and odor. The external packaging of Onradivir tablet and the placebo is identical. Take placebo once daily, 3 tablets per dose, for a total of 5 days (5 doses).
Take Onradivir Tablets once daily, 600 mg (3 tablets) per dose, for a total of 5 days (5 doses).
Time to alleviation of influenza symptoms
Time frame: Up to Day 15
Time to fever resolution
axillary temperature ≤37.2°C
Time frame: Up to Day 15
Change from baseline in influenza A viral quantification
Change from baseline in influenza A viral quantification (viral titer and viral RNA load)
Time frame: Up to Day 15
Duration of detectable viral titer and viral RNA load
Time frame: Up to Day 15
Proportion of participants with positive viral titer and viral load
Time frame: Up to Day 15
Area under the curve of viral quantification versus time
Area under the curve (AUC) of viral quantification (viral titer and viral RNA load) versus time
Time frame: Up to Day 15
Incidence of influenza-related complications
Incidence of influenza-related complications (hospitalization, death, sinusitis, bronchitis, otitis media, pneumonia, myocarditis, pericarditis, neurological complications, musculoskeletal complications, etc.)
Time frame: Up to Day 15
Proportion of participants with symptom resolution
Time frame: Up to Day 15
Time to resolution of systemic symptoms
Time to resolution of systemic symptoms (headache, fever or chills, muscle or joint pain, fatigue)
Time frame: Up to Day 15
Time to resolution of respiratory symptoms
Time to resolution of respiratory symptoms (cough, sore throat, nasal congestion)
Time frame: Up to Day 15
Time to resolution of individual symptoms
Time frame: Up to Day 15
Proportion of participants with fever resolution
Time frame: Up to Day 15
Proportion and frequency of participants using symptomatic treatment medications
Time frame: Up to Day 15
Time to return to normal daily activities
Time frame: Up to Day 15
Plan to share: Yes
No publications or documents are linked to this record.
Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.
Of 35 non-industry phase 3 interventional studies under Influenza, Human, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 41. This study's planned 12 months is below that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.